Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Chief Executive Change At Teva Illustrates Diversification Emphasis At Major Generic Drug Makers

Executive Summary

Most of the top 20 generic drug makers are subsidiaries of diversified pharmas or smaller generics-only plays based in the Far East. But diversification, although long a goal, is now urgent for the three major independent generic firms – Teva, Mylan and Watson.


Related Content

Teva Makes The Cut: 5,000 Jobs To Be Eliminated
Former “String Of Pearls” Strategist Tabbed To Lead Teva’s Continuing Diversification
Amgen, Watson Aim To Launch First Joint Oncology Biosimilar In U.S. In 2017
Teva Buys Majority Stake In Japanese Generics Company For $460 Mil.
With Cephalon Deal, Teva Sees Opportunities For Niche Branded Drugs and Drug/Device Combinations
In Cephalon, Teva Will Get An Expanded Innovative R&D And Branded Portfolio
Teva Stakes OTC Claim With P&G Joint Venture
Despite Short-Term Glitches, Teva Maintains It Is On Track To Double Revenues By 2015
Watson Talks Up Prochieve And Global Expansion At Analyst Meeting
Mylan Closes Merck KGaA Merger, Looks To Fill Remaining Pipeline Gaps


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts